Table 3.
Adverse events
| Treatment–1 month | >1–6 months | >6–12 months | ||||
|---|---|---|---|---|---|---|
| Events | Patients | Events | Patients | Events | Patients | |
| Serious respiratory adverse events | ||||||
| COPD exacerbation | 7 | 7 | 12 | 10 | 4 | 3 |
| Pneumonia | 6 | 5 | 3 | 3 | 6 | 6 |
| Haemoptysis | 1 | 1 | 0 | 0 | 0 | 0 |
| Pneumothorax | 4 | 4 | 2 | 2 | 1 | 1 |
| Respiratory adverse events | ||||||
| COPD exacerbation | 8 | 7 | 21 | 15 | 19 | 15 |
| Pneumonia | 5 | 3 | 4 | 3 | 3 | 3 |
| Mild haemoptysis (<5 mL) | 61 | 35 | 3 | 3 | 2 | 2 |
| Cough | 2 | 2 | 3 | 3 | 0 | 0 |
| Transient chest pain | 28 | 20 | 7 | 6 | 3 | 3 |
Adverse events presented per procedure for the first month after each procedure (115 procedures in total), for patients in the 1–6 month follow-up period (n=58) and for patients in the 6–12 month follow-up period (n=35). Events reported for both unilateral and bilateral treated patients.
COPD, chronic obstructive pulmonary disease.